Technological advances in wearables and sensors are speeding the development of digital measures and endpoints throughout the drug development process and across therapeutic areas and patient populations. The pandemic subsequently drove broader acceptance from patients, researchers, clinicians, regulators, and the general public about the role of this technology and the prevalence of decentralized clinical trial
Comments